Hepatitis Monthly

Published by: Kowsar

The Role of Interleukin-28b Gene Polymorphisms in Chinese Patients With Chronic Hepatitis C Treated With Pegylated Interferon and Ribavirin

Yin Mi 1 , 2 , Ying Tang Gao 1 , Xiao Lei Jiao 1 , Hua Guo 1 , Tong Liu 1 , Li Jing 1 , Wen Xia Shi 1 and Zhi Du 1 , *
Authors Information
1 Key Laboratory of Artificial Cell, Tianjin Third Central Hospital, Tianjin, China
2 Radiotherapy Department, First Affiliated Hospital, Zhengzhou University, Henan, China
Article information
  • Hepatitis Monthly: August 2014, 14 (8); e18793
  • Published Online: August 9, 2014
  • Article Type: Research Article
  • Received: March 6, 2014
  • Revised: May 4, 2014
  • Accepted: July 5, 2014
  • DOI: 10.5812/hepatmon.18793

To Cite: Mi Y, Gao Y T, Jiao X L, Guo H, Liu T, et al. The Role of Interleukin-28b Gene Polymorphisms in Chinese Patients With Chronic Hepatitis C Treated With Pegylated Interferon and Ribavirin, Hepat Mon. 2014 ;14(8):e18793. doi: 10.5812/hepatmon.18793.

Copyright: Copyright © 2014, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Hepatitis C. 2012;
  • 2. Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002; 36(5 Suppl 1)-46[DOI][PubMed]
  • 3. Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver D. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009; 49(4): 1335-74[DOI][PubMed]
  • 4. Zeuzem S, Berg T, Moeller B, Hinrichsen H, Mauss S, Wedemeyer H, et al. Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat. 2009; 16(2): 75-90[DOI][PubMed]
  • 5. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358(9286): 958-65[PubMed]
  • 6. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347(13): 975-82[DOI][PubMed]
  • 7. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010; 138(4): 1338-45[DOI][PubMed]
  • 8. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009; 41(10): 1100-4[DOI][PubMed]
  • 9. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009; 41(10): 1105-9[DOI][PubMed]
  • 10. Ochi H, Maekawa T, Abe H, Hayashida Y, Nakano R, Imamura M, et al. IL-28B predicts response to chronic hepatitis C therapy--fine-mapping and replication study in Asian populations. J Gen Virol. 2011; 92: 1071-81[DOI][PubMed]
  • 11. Lyoo K, Song MJ, Hur W, Choi JE, Hong SW, Kim CW, et al. Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin. J Clin Virol. 2011; 52(4): 363-6[DOI][PubMed]
  • 12. Venegas M, Villanueva RA, Gonzalez K, Brahm J. IL28B polymorphisms associated with therapy response in Chilean chronic hepatitis C patients. World J Gastroenterol. 2011; 17(31): 3636-9[DOI][PubMed]
  • 13. Hsu CS, Hsu SJ, Chen HC, Tseng TC, Liu CH, Niu WF, et al. Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. Proc Natl Acad Sci U S A. 2011; 108(9): 3719-24[DOI][PubMed]
  • 14. Chen JY, Lin CY, Wang CM, Lin YT, Kuo SN, Shiu CF, et al. IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-alpha plus ribavirin therapy in Taiwanese chronic HCV infection. Genes Immun. 2011; 12(4): 300-9[DOI][PubMed]
  • 15. Sinn DH, Kim YJ, Lee ST, Gwak GY, Choi MS, Lee JH, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian patients. J Gastroenterol Hepatol. 2011; 26(9): 1374-9[DOI][PubMed]
  • 16. Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, Alomair A, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int. 2011; 31 Suppl 2: 61-80[DOI][PubMed]
  • 17. Park JC, Kim JM, Kwon OJ, Lee KR, Chai YG, Oh HB. Development and clinical evaluation of a microarray for hepatitis C virus genotyping. J Virol Methods. 2010; 163(2): 269-75[DOI][PubMed]
  • 18. Ito K, Higami K, Masaki N, Sugiyama M, Mukaide M, Saito H, et al. The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B. J Clin Microbiol. 2011; 49(5): 1853-60[DOI][PubMed]
  • 19. Ridruejo E, Solano A, Marciano S, Galdame O, Adrover R, Cocozzella D, et al. Genetic variation in interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin. Ann Hepatol. 2011; 10(4): 452-7[PubMed]
  • 20. Imazeki F, Yokosuka O, Omata M. Impact of IL-28B SNPs on control of hepatitis C virus infection: a genome-wide association study. Expert Rev Anti Infect Ther. 2010; 8(5): 497-9[DOI][PubMed]
  • 21. Idrees M, Riazuddin S. A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients. BMC Gastroenterol. 2009; 9: 5[DOI][PubMed]
  • 22. Weich V, Herrmann E, Chung TL, Sarrazin C, Hinrichsen H, Buggisch P, et al. The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection. J Gastroenterol. 2011; 46(12): 1427-36[DOI][PubMed]
  • 23. Hofmann WP, Zeuzem S. A new standard of care for the treatment of chronic HCV infection. Nat Rev Gastroenterol Hepatol. 2011; 8(5): 257-64[DOI][PubMed]
  • 24. Tsubota A, Fujise K, Namiki Y, Tada N. Peginterferon and ribavirin treatment for hepatitis C virus infection. World J Gastroenterol. 2011; 17(4): 419-32[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader